Finasteride and flutamide as potency-sparing androgen-ablative therapy for advanced adenocarcinoma of the prostate

Author： Brufsky A. Fontaine-Rothe P. Berlane K. Rieker P. Jiroutek M. Kaplan I. Kaufman D. Kantoff P.

Publisher： Elsevier

ISSN： 0090-4295

Source： Urology, Vol.49, Iss.6, 1997-06, pp. : 913-920

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Combined finasteride and flutamide therapy in men with advanced prostate cancer

By Ornstein D.K. Rao G.S. Johnson B. Charlton E.T. Andriole G.L.

Urology, Vol. 48, Iss. 6, 1996-12 ,pp. : 901-905

Elsevier

Access to resources Recommend Favorite

Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up

By Oh W.K. Manola J. Bittmann L. Brufsky A. Kaplan I.D. Smith M.R. Kaufman D.S. Kantoff P.W.

Urology, Vol. 62, Iss. 1, 2003-07 ,pp. : 99-104

Elsevier

Access to resources Recommend Favorite

Biochemical response to testicular androgen ablation among patients with prostate cancer for whom flutamide and/or finasteride therapy failed - a meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens

By Ornstein D.K. Smith D.S. Andriole G.L.

Urology, Vol. 52, Iss. 6, 1998-12 ,pp. : 1094-1097

Elsevier

Access to resources Recommend Favorite

Hormonal therapy for patients with advanced adenocarcinoma of the prostate: is there a role for discontinuing treatment after prolonged androgen suppression?

By Pedraza R. Kwart A.M.

Urology, Vol. 61, Iss. 4, 2003-04 ,pp. : 770-773

Elsevier

Access to resources Recommend Favorite

Combination of low-dose flutamide and finasteride for PSA-only recurrent prostate cancer after primary therapy

By Barqawi A.B. Moul J.W. Ziada A. Handel L. Crawford E.D.

Urology, Vol. 62, Iss. 5, 2003-11 ,pp. : 872-876

Elsevier

Access to resources Recommend Favorite